Please note: The information displayed on this page might be outdated.
Immunocore: Pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, infectious and autoimmune disease. MAGE-A4 Phase 1 Data Q4 2021, tebentafusp PDUFA target action date Feb. 2022, PRAME Phase 1 Data Mid-2022.
Based in...
Clinical Stage
Phase III, Phase l or ll
Disease Space
Immuno-Oncology, Oncology, Rare Disease
Public, USA
Market Cap
1B +
Therapeutic Modalities
Cell Therapy
Abingdon, Oxfordshire
United Kingdom

Company Participants at Immunocore MAGE-A4 Investor & Analyst Event 2021

  • Bahija Jallal, CEO

Top 10 Holders of Immunocore Holdings Plc Sponsored ADR

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Rock Springs Capital Management LP 5.82 2,552,034 77.10 13F 3/31/22
Baker Bros. Advisors LP 5.75 2,520,730 76.15 13F 3/31/22
RTW Investments LP 4.24 1,859,471 56.17 13F 3/31/22
Avidity Partners Management LP 3.11 1,363,800 41.20 13F 3/31/22
Wellington Management Co. LLP 3.06 1,342,359 40.55 13F 3/31/22
Fidelity Management & Research Co. LLC 2.81 1,231,831 37.21 13F 3/31/22
General Atlantic LLC 2.17 950,000 28.70 13F 3/31/22
First Manhattan Co. 1.84 808,549 24.43 13F 3/31/22
Bill & Melinda Gates Foundation 1.32 576,923 17.43 13F 3/31/22
Paradigm BioCapital Advisors LP 1.14 499,190 15.08 13F 3/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.